<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33012782</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-1827</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>124</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>British journal of cancer</Title>
          <ISOAbbreviation>Br J Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.</ArticleTitle>
        <Pagination>
          <StartPage>383</StartPage>
          <EndPage>390</EndPage>
          <MedlinePgn>383-390</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41416-020-01099-7</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">EGFR tyrosine kinase inhibitors (TKIs) induce cytolysis and release of tumour proteins, which can stimulate antigen-specific T cells. The safety and efficacy of durvalumab and gefitinib in combination for TKI-naive patients with advanced EGFRm NSCLC was evaluated.</AbstractText>
          <AbstractText Label="METHODS">This Phase 1 open-label, multicentre trial (NCT02088112) was conducted in 56 patients with NSCLC. Dose expansion permitted TKI-naive patients, primarily with activating L858R or Ex19del EGFRm. Arms 1 + 1a received concurrent therapy; Arm 2 received 4 weeks of gefitinib induction followed by concurrent therapy.</AbstractText>
          <AbstractText Label="RESULTS">From dose escalation, the recommended dose of durvalumab was 10 mg/kg Q2W with 250 mg QD gefitinib. Pharmacokinetics were as expected, consistent with inhibition of soluble PD-L1 and no treatment-emergent immunogenicity. In dose expansion, 35% of patients had elevated liver enzymes leading to drug discontinuation. In Arms 1 + 1a, objective response rate was 63.3% (95% CI: 43.9-80.1), median progression-free survival (PFS) was 10.1 months (95% CI: 5.5-15.2) and median response duration was 9.2 months (95% CI: 3.7-14.0).</AbstractText>
          <AbstractText Label="CONCLUSIONS">Durvalumab and gefitinib in combination had higher toxicity than either agent alone. No significant increase in PFS was detected compared with historical controls. Therefore, concurrent PD-L1 inhibitors with gefitinib should be generally avoided in TKI-naive patients with EGFRm NSCLC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Creelan</LastName>
            <ForeName>Benjamin C</ForeName>
            <Initials>BC</Initials>
            <Identifier Source="ORCID">0000-0002-2728-8070</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, FOB-1, Tampa, FL, 33612, USA. Ben.Creelan@moffitt.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yeh</LastName>
            <ForeName>Tammie C</ForeName>
            <Initials>TC</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Medicine, Oncology R&amp;D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Sang-We</ForeName>
            <Initials>SW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nogami</LastName>
            <ForeName>Naoyuki</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, 160 Minami-Umemoto-cho, Matsuyama City, 791-0280, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Dong-Wan</ForeName>
            <Initials>DW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chow</LastName>
            <ForeName>Laura Q M</ForeName>
            <Initials>LQM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, WA, 98109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kanda</LastName>
            <ForeName>Shintaro</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, 3-1-1 Asahi Matsumoto, Nagano, 390-8621, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taylor</LastName>
            <ForeName>Rosemary</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology, AstraZeneca, Academy House, 132-136 Hills Road, Cambridge, CB2 8PA, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Weifeng</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology and Safety Assessment, AstraZeneca, One Medimmune Way, 101 ORD, 2001D, Gaithersburg, MD, 20878, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Mei</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology and Safety Assessment, AstraZeneca, One Medimmune Way, 101 ORD, 2001D, Gaithersburg, MD, 20878, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Angell</LastName>
            <ForeName>Helen K</ForeName>
            <Initials>HK</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Medicine, Oncology R&amp;D, AstraZeneca, Darwin Building, Unit 310, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roudier</LastName>
            <ForeName>Martine P</ForeName>
            <Initials>MP</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Medicine, Oncology R&amp;D, AstraZeneca, Darwin Building, Unit 310, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marotti</LastName>
            <ForeName>Marcelo</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology, AstraZeneca, Academy House, 132-136 Hills Road, Cambridge, CB2 8PA, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gibbons</LastName>
            <ForeName>Don L</ForeName>
            <Initials>DL</Initials>
            <Identifier Source="ORCID">0000-0003-2362-3094</Identifier>
            <AffiliationInfo>
              <Affiliation>Departments of Thoracic/Head and Neck Medical Oncology and Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02088112</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Br J Cancer</MedlineTA>
        <NlmUniqueID>0370635</NlmUniqueID>
        <ISSNLinking>0007-0920</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>28X28X9OKV</RegistryNumber>
          <NameOfSubstance UI="C000613593">durvalumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>B.C.C. has received institutional research grants/supplies from Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Iovance Biotherapeutics, Neogenomics and Prometheus; participated in speaker bureaus for Achilles, AstraZeneca, Bristol-Myers Squibb, Foundation Medicine, F. Hoffmann-La Roche AG, Gilead and Takeda; and has participated in advisory boards for AbbVie, BergenBio, Bristol-Myers Squibb and GlaxoSmithKline. T.C.Y., R.T., W.T. and H.K.A. are employees or contracted employees of AstraZeneca and may be shareholders of AstraZeneca. S.-W.K. has received clinical research support from AstraZeneca, Boehringer Ingelheim and Eli Lilly. N.N. has received research grants from AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, Kyowa Hakko Kirin, ONO Pharmaceutical and Taiho Pharmaceutical and personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, Kyowa Hakko Kirin, Meiji Seika Pharma, Merck Sharp &amp; Dohme, Nikkei Business Publications, ONO Pharmaceutical, Pfizer Japan, Reno Medical and Taiho Pharmaceutical. D.-W.K’s institution has received research funding from Alpha Biopharma, AstraZeneca/MedImmune, Hanmi, Janssen, Merus, Mirati Therapeutics, MSD, Novartis, ONO Pharmaceutical, Pfizer Inc., Roche/Genentech, Takeda, TP Therapeutics, Xcovery and Yuhan. L.Q.M.C. is an employee of the University of Texas, Austin and a former employee of the University of Washington/Seattle Cancer Care Alliance. L.Q.M.C’s institution has received research funding from Alkermes, AstraZeneca/MedImmune, Bristol-Myers Squibb, Dynavax, Eli Lilly, Genentech, Incyte, Merck, Novartis, Pfizer Inc., Seattle Genetics and VentiRx; and the University of Washington/Seattle Cancer Care Alliance received institutional funding from AstraZeneca for this study. L.Q.M.C. has received honoraria from Amgen and has participated in advisory boards for Alkermes, Amgen, AstraZeneca, Bristol-Myers Squibb, Dynavax, Genentech, Merck, Novartis, Pfizer Inc., Sanofi Genzyme, Seattle Genetics, Synthorx and Takeda. S.K. has received research grant funding from AbbVie, AstraZeneca and ONO Pharmaceutical; honoraria from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Novartis and ONO Pharmaceutical; and has participated in advisory boards for AstraZeneca. M.T. is an employee of Astellas Pharma US and a former employee of AstraZeneca. M.P.R. is an employee of the Institute for Prostate Cancer Research and a former employee of AstraZeneca. M.M. is a former employee of AstraZeneca. D.L.G. has received research grants from AstraZeneca, Janssen Research &amp; Development and Takeda; has participated in advisory boards for AstraZeneca, GlaxoSmithKline and Sanofi; and has received travel expenses from AstraZeneca. D.L.G’s institution has received compensation for conducting the study.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33012782</ArticleId>
        <ArticleId IdType="pmc">PMC7852511</ArticleId>
        <ArticleId IdType="doi">10.1038/s41416-020-01099-7</ArticleId>
        <ArticleId IdType="pii">10.1038/s41416-020-01099-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al.  Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 2018;378:113–125. doi: 10.1056/NEJMoa1713137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1713137</ArticleId>
            <ArticleId IdType="pubmed">29151359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, et al.  Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial. Ann. Oncol. 2016;27:417–423. doi: 10.1093/annonc/mdv597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdv597</ArticleId>
            <ArticleId IdType="pmc">PMC4769992</ArticleId>
            <ArticleId IdType="pubmed">26646759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141–151. doi: 10.1016/S1470-2045(14)71173-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)71173-8</ArticleId>
            <ArticleId IdType="pubmed">25589191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Creelan, B., Gray, J., Lima, D., Antonia, S., Chiappori, A., Tanvetyanon, T. et al. Abstract CT060. Efficacy, safety and tolerability of dasatinib combined with afatinib: a phase I trial in patients with epidermal growth factor receptor mutant (EGFRm) advanced non-small-cell lung cancer (NSCLC) after acquired tyrosine kinase inhibitor (TKI) resistance. Cancer Res. 76, CT060 (2016).</Citation>
        </Reference>
        <Reference>
          <Citation>Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009;361:947–957. doi: 10.1056/NEJMoa0810699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0810699</ArticleId>
            <ArticleId IdType="pubmed">19692680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosell, R., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Cardenal, F. et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J. Clin. Oncol. 29, 7503 (2011).</Citation>
        </Reference>
        <Reference>
          <Citation>Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010;362:2380–2388. doi: 10.1056/NEJMoa0909530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0909530</ArticleId>
            <ArticleId IdType="pubmed">20573926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al.  Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015;373:1627–1639. doi: 10.1056/NEJMoa1507643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1507643</ArticleId>
            <ArticleId IdType="pmc">PMC5705936</ArticleId>
            <ArticleId IdType="pubmed">26412456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550. doi: 10.1016/S0140-6736(15)01281-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(15)01281-7</ArticleId>
            <ArticleId IdType="pubmed">26712084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–265. doi: 10.1016/S0140-6736(16)32517-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)32517-X</ArticleId>
            <ArticleId IdType="pmc">PMC6886121</ArticleId>
            <ArticleId IdType="pubmed">27979383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gettinger S, Hellmann M, Chow L, Borghaei H, Antonia S, Brahmer J, et al.  Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC. J. Thorac. Oncol. 2018;13:1363–1372. doi: 10.1016/j.jtho.2018.05.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2018.05.015</ArticleId>
            <ArticleId IdType="pubmed">29802888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, et al.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18:31–41. doi: 10.1016/S1470-2045(16)30624-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(16)30624-6</ArticleId>
            <ArticleId IdType="pmc">PMC5476941</ArticleId>
            <ArticleId IdType="pubmed">27932067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Lian Z, Wang S, Xing L, Yu J. Interactions between EGFR and PD-1/PD-L1 pathway: implications for treatment of NSCLC. Cancer Lett. 2018;418:1–9. doi: 10.1016/j.canlet.2018.01.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2018.01.005</ArticleId>
            <ArticleId IdType="pubmed">29309815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia J, Li X, Jiang T, Zhao S, Zhao C, Zhang L, et al.  EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: implications for combination therapies. Int. J. Cancer. 2019;145:1432–1444. doi: 10.1002/ijc.32191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.32191</ArticleId>
            <ArticleId IdType="pubmed">30784054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lizotte PH, Hong R-L, Luster TA, Cavanaugh ME, Taus LJ, Wang S, et al.  A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing. Cancer Immunol. Res. 2018;6:1511–1523. doi: 10.1158/2326-6066.CIR-18-0193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-18-0193</ArticleId>
            <ArticleId IdType="pmc">PMC6601346</ArticleId>
            <ArticleId IdType="pubmed">30242021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lulli D, Carbone ML, Pastore S. Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin. Oncotarget. 2016;7:47777–47793. doi: 10.18632/oncotarget.10013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.10013</ArticleId>
            <ArticleId IdType="pmc">PMC5216978</ArticleId>
            <ArticleId IdType="pubmed">27322144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thress K, Jacobs V, Angell H, Yang J, Sequist L, Blackhall F, et al.  Modulation of biomarker expression by osimertinib: results of the paired tumor biopsy cohorts of the AURA phase I trial. J. Thorac. Oncol. 2017;12:1588–1594. doi: 10.1016/j.jtho.2017.07.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2017.07.011</ArticleId>
            <ArticleId IdType="pubmed">28751247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollack BP, Sapkota B, Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin. Cancer Res. 2011;17:4400–4413. doi: 10.1158/1078-0432.CCR-10-3283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-3283</ArticleId>
            <ArticleId IdType="pubmed">21586626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumai T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Harabuchi Y, et al.  EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy. Br. J. Cancer. 2013;109:2155–2166. doi: 10.1038/bjc.2013.577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2013.577</ArticleId>
            <ArticleId IdType="pmc">PMC3798972</ArticleId>
            <ArticleId IdType="pubmed">24045666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Champiat S, Ileana E, Giaccone G, Besse B, Mountzios G, Eggermont A, et al.  Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J. Thorac. Oncol. 2014;9:144–153. doi: 10.1097/JTO.0000000000000074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JTO.0000000000000074</ArticleId>
            <ArticleId IdType="pubmed">24419410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurule NJ, Heasley LE. Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses. Cancer Drug Resist. 2018;1:118–125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6333470</ArticleId>
            <ArticleId IdType="pubmed">30656289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunimasa K, Nakamura H, Sakai K, Kimura M, Inoue T, Tamiya M, et al.  Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor. Ann. Oncol. 2018;29:2145–2147. doi: 10.1093/annonc/mdy312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy312</ArticleId>
            <ArticleId IdType="pubmed">30099497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, et al.  EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin. Cancer Res. 2016;22:4585–4593. doi: 10.1158/1078-0432.CCR-15-3101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-3101</ArticleId>
            <ArticleId IdType="pmc">PMC5026567</ArticleId>
            <ArticleId IdType="pubmed">27225694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al.  PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br. J. Cancer. 2015;112:95–102. doi: 10.1038/bjc.2014.555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2014.555</ArticleId>
            <ArticleId IdType="pmc">PMC4453606</ArticleId>
            <ArticleId IdType="pubmed">25349974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt L, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch J, et al.  PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS ONE. 2015;10:e0136023. doi: 10.1371/journal.pone.0136023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0136023</ArticleId>
            <ArticleId IdType="pmc">PMC4552388</ArticleId>
            <ArticleId IdType="pubmed">26313362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, et al.  The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget. 2015;6:14209–14219. doi: 10.18632/oncotarget.3694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.3694</ArticleId>
            <ArticleId IdType="pmc">PMC4546461</ArticleId>
            <ArticleId IdType="pubmed">25895031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su S, Dong Z-Y, Xie Z, Yan L-X, Li Y-F, Su J, et al.  Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation. J. Thorac. Oncol. 2018;13:1668–1675. doi: 10.1016/j.jtho.2018.07.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2018.07.016</ArticleId>
            <ArticleId IdType="pubmed">30056164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, et al.  Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2019;25:1063–1069. doi: 10.1158/1078-0432.CCR-18-1102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-1102</ArticleId>
            <ArticleId IdType="pmc">PMC6347551</ArticleId>
            <ArticleId IdType="pubmed">30045933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, et al.  Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol. Res. 2015;3:1052–1062. doi: 10.1158/2326-6066.CIR-14-0191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0191</ArticleId>
            <ArticleId IdType="pubmed">25943534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, et al.  Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018;19:521–536. doi: 10.1016/S1470-2045(18)30144-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30144-X</ArticleId>
            <ArticleId IdType="pmc">PMC7771363</ArticleId>
            <ArticleId IdType="pubmed">29545095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolf M, Swaisland H, Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin. Cancer Res. 2004;10:4607–4613. doi: 10.1158/1078-0432.CCR-04-0058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-04-0058</ArticleId>
            <ArticleId IdType="pubmed">15269131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He S, Yin T, Li D, Gao X, Wan Y, Ma X, et al.  Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation. J. Transl. Med. 2013;11:1–11. doi: 10.1186/1479-5876-11-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-5876-11-1</ArticleId>
            <ArticleId IdType="pmc">PMC3766712</ArticleId>
            <ArticleId IdType="pubmed">23937717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edge, S., Byrd, D. R., Compton, C. C., Fritz, A. G., Greene, F. L. &amp; Trotti, A. AJCC Cancer Staging Manual 7th edn (Springer, New York, NY, 2010).</Citation>
        </Reference>
        <Reference>
          <Citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur. J. Cancer. 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2008.10.026</ArticleId>
            <ArticleId IdType="pubmed">19097774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rebelatto M, Midha A, Mistry A, Sabalos C, Schechter N, Li X, et al.  Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn. Pathol. 2016;11:95. doi: 10.1186/s13000-016-0545-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13000-016-0545-8</ArticleId>
            <ArticleId IdType="pmc">PMC5055695</ArticleId>
            <ArticleId IdType="pubmed">27717372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roche. VENTANA PD-L1 (SP263) assay (CE IVD). https://diagnostics.roche.com/global/en/products/tests/ventana-pd-l1-_sp263-assay2.html (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Baverel P, Dubois V, Jin C, Zheng Y, Song X, Jin X, et al.  Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin. Pharmacol. Ther. 2018;103:631–642. doi: 10.1002/cpt.982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cpt.982</ArticleId>
            <ArticleId IdType="pmc">PMC5887840</ArticleId>
            <ArticleId IdType="pubmed">29243223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, et al.  Single-dose clinical pharmacokinetic studies of gefitinib. Clin. Pharmacokinet. 2005;44:1165–1177. doi: 10.2165/00003088-200544110-00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00003088-200544110-00004</ArticleId>
            <ArticleId IdType="pubmed">16231967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Douillard J-Y, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, et al.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open label, single arm study. Br. J. Cancer. 2014;110:55–62. doi: 10.1038/bjc.2013.721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2013.721</ArticleId>
            <ArticleId IdType="pmc">PMC3887309</ArticleId>
            <ArticleId IdType="pubmed">24263064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rudin, C., Cervantes, A., Dowlati, A., Besse, B., Ma, B., Costa, D. et al. Abstract MA15.02 Long-term safety and clinical activity results from a Phase Ib study of erlotinib plus atezolizumab in advanced NSCLC. J. Thorac. Oncol. 13, MA15.02 (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>Yang J, Gadgeel S, Sequist L, Wu C, Papadimitrakopoulou V, Su W, et al.  Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation. J. Thorac. Oncol. 2019;14:553–559. doi: 10.1016/j.jtho.2018.11.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2018.11.028</ArticleId>
            <ArticleId IdType="pubmed">30529597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teo Y, Ho H, Chan A. Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. Expert Opin. Drug Metab. Toxicol. 2015;11:231–242. doi: 10.1517/17425255.2015.983075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/17425255.2015.983075</ArticleId>
            <ArticleId IdType="pubmed">25400226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US Food and Drug Administration. Osimertinib highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>Ahn, M.-J., Yang, J., Yu, H., Saka, H., Ramalingam, S., Goto, K. et al. Abstract 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J. Thorac. Oncol. 11, 136O (2016).</Citation>
        </Reference>
        <Reference>
          <Citation>Chih-Hsin Yang J, Shepherd F, Kim D, Lee G, Lee J, Chang G, et al.  Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR-TKI therapy: CAURAL brief report. J. Thorac. Oncol. 2019;14:933–939. doi: 10.1016/j.jtho.2019.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2019.02.001</ArticleId>
            <ArticleId IdType="pubmed">30763730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, et al.  Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell lung cancer (CheckMate 370) J. Thorac. Oncol. 2018;13:682–688. doi: 10.1016/j.jtho.2018.02.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2018.02.022</ArticleId>
            <ArticleId IdType="pubmed">29518553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, et al.  A Phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J. Thorac. Oncol. 2018;13:1138–1145. doi: 10.1016/j.jtho.2018.03.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2018.03.035</ArticleId>
            <ArticleId IdType="pmc">PMC6063769</ArticleId>
            <ArticleId IdType="pubmed">29874546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown, H., Vansteenkiste, J., Nakagawa, K., Cobo Dols, M., John, T., Barker, C. et al. MA15.03 PD-L1 expression in untreated EGFRm advanced NSCLC and response to osimertinib and SoC EGFR-TKIs in the FLAURA trial. J. Thorac. Oncol. 13, MA15.03 (2018).</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
